Table 2.

Patients who developed new-onset PsA during biologic treatment: general features, treatment, and PsA severity. MTX: methotrexate, SSZ: sulfasalazine, CS: oral corticosteroids.

Patient	Sex	Age	Psoriasis Duration	Biologic Treatment	Treatment Duration	Therapy Following the Diagnosis of PsA	PsA Severity
1	Female	35	17	Adalimumab	12	Ixekizumab	Moderate
2	Male	52	15	Secukinumab	32	Secukinumab + MTX	Moderate
3	Female	30	10	Ustekinumab	60	Ustekinumab + CS	Mild
4	Female	46	3	Adalimumab	18	Secukinumab	Severe
5	Female	50	30	Etanercept	56	Certolizumab	Severe
6	Female	27	7	Ustekinumab	18	Ustekinumab + SSZ	Mild
7	Female	38	21	Brodalumab	3	Brodalumab + MTX	Moderate
8	Male	73	5	Ixekizumab	12	Ixekizumab + MTX	Moderate
9	Male	42	14	Secukinumab	48	Secukinumab + CS	Mild
10	Female	52	20	Risankizumab	2	Risankizumab + MTX	Mild